Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Coronaviruses
  4. Fast Track Articles
  5. Fast Track Article
image of COVID 19: Variants, Diagnosis and Vaccines- An Update

Abstract

In 2019, a life-threatening virus, SARS-Cov 2 emerged in China and caused destruction all around the world, affecting many lives; the origin of this virus is still debatable and unclear. The coronavirus is a contagious disease with high rates of transmission; it mutates rapidly and now has variants, some of which have caused a lot of damage to lives and the economy. These variants are mainly classified into three main groups: a) variants of concern; b) variants of interest; and c) variants under monitoring. Vaccines are the safest and most effective option for preventing covid and saving lives, as building immunity and breaking the chain of transmission is essential even though vaccines that have been developed till now have different effects against different variants of coronavirus. As it is known that vaccines are the main shield to protect from coronavirus, due to rapid mutation and slow developments of vaccines several people are still getting infected with covid-19. Many treatment options are available, such as antiviral drugs, nanotechnology, plasma therapy, and monoclonal antibodies. Besides prevention and treatment, correct diagnosis of the disease is essential, and for this purpose, different diagnostic techniques are discussed in this article alongside the possible future of COVID-19.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975278624241224101531
2024-12-30
2025-01-19

  • From This Site

    /content/journals/covid/10.2174/0126667975278624241224101531
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Cucinotta D. Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020 91 1 157 160 32191675
    [Google Scholar]
  2. Greenhalgh T. Sivan M. Perlowski A. Nikolich J.Ž. Long COVID: A clinical update. Lancet 2024 404 10453 707 724 10.1016/S0140‑6736(24)01136‑X 39096925
    [Google Scholar]
  3. Machhi J. Herskovitz J. Senan A.M. Dutta D. Nath B. Oleynikov M.D. Blomberg W.R. Meigs D.D. Hasan M. Patel M. Kline P. Chang R.C.C. Chang L. Gendelman H.E. Kevadiya B.D. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J. Neuroimmune Pharmacol. 2020 15 3 359 386 10.1007/s11481‑020‑09944‑5 32696264
    [Google Scholar]
  4. Eising E. Mirza-Schreiber N. de Zeeuw E.L. Wang C.A. Truong D.T. Allegrini A.G. Shapland C.Y. Zhu G. Wigg K.G. Gerritse M.L. Molz B. Alagöz G. Gialluisi A. Abbondanza F. Rimfeld K. van Donkelaar M. Liao Z. Jansen P.R. Andlauer T.F.M. Bates T.C. Bernard M. Blokland K. Bonte M. Børglum A.D. Bourgeron T. Brandeis D. Ceroni F. Csépe V. Dale P.S. de Jong P.F. DeFries J.C. Démonet J.F. Demontis D. Feng Y. Gordon S.D. Guger S.L. Hayiou-Thomas M.E. Hernández-Cabrera J.A. Hottenga J.J. Hulme C. Kere J. Kerr E.N. Koomar T. Landerl K. Leonard G.T. Lovett M.W. Lyytinen H. Martin N.G. Martinelli A. Maurer U. Michaelson J.J. Moll K. Monaco A.P. Morgan A.T. Nöthen M.M. Pausova Z. Pennell C.E. Pennington B.F. Price K.M. Rajagopal V.M. Ramus F. Richer L. Simpson N.H. Smith S.D. Snowling M.J. Stein J. Strug L.J. Talcott J.B. Tiemeier H. van der Schroeff M.P. Verhoef E. Watkins K.E. Wilkinson M. Wright M.J. Barr C.L. Boomsma D.I. Carreiras M. Franken M.C.J. Gruen J.R. Luciano M. Müller-Myhsok B. Newbury D.F. Olson R.K. Paracchini S. Paus T. Plomin R. Reilly S. Schulte-Körne G. Tomblin J.B. van Bergen E. Whitehouse A.J.O. Willcutt E.G. St Pourcain B. Francks C. Fisher S.E. Genome-wide analyses of individual differences in quantitatively assessed reading- and language-related skills in up to 34,000 people. Proc. Natl. Acad. Sci. USA 2022 119 35 e2202764119 10.1073/pnas.2202764119 35998220
    [Google Scholar]
  5. Donald J. Bilasy S.E. Yang C. El-Shamy A. Exploring the complexities of long COVID. Viruses 2024 16 7 1060 10.3390/v16071060 39066223
    [Google Scholar]
  6. Wang D. Wu X. Li C. Han J. Yin J. The impact of geo-environmental factors on global COVID-19 transmission: A review of evidence and methodology. Sci. Total Environ. 2022 826 154182 10.1016/j.scitotenv.2022.154182 35231530
    [Google Scholar]
  7. Andrews H.S. Herman J.D. Gandhi R.T. Treatments for COVID-19. Annu. Rev. Med. 2024 75 1 145 157 10.1146/annurev‑med‑052422‑020316 37722709
    [Google Scholar]
  8. Zhou Z. Zhu Y. Chu M. Role of COVID-19 vaccines in SARS-CoV-2 variants. Front. Immunol. 2022 13 898192 10.3389/fimmu.2022.898192 35669787
    [Google Scholar]
  9. Chenchula S. Karunakaran P. Sharma S. Chavan M. Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review. J. Med. Virol. 2022 94 7 2969 2976 10.1002/jmv.27697 35246846
    [Google Scholar]
  10. El-Shabasy R.M. Nayel M.A. Taher M.M. Abdelmonem R. Shoueir K.R. Kenawy E.R. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. Int. J. Biol. Macromol. 2022 204 161 168 10.1016/j.ijbiomac.2022.01.118 35074332
    [Google Scholar]
  11. Guo S. Liu K. Zheng J. The genetic variant of SARS-CoV-2: Would it matter for controlling the devastating pandemic? Int. J. Biol. Sci. 2021 17 6 1476 1485 10.7150/ijbs.59137 33907511
    [Google Scholar]
  12. Guo H. Fan Q. Song S. Shen S. Zhou B. Wang H. Cheng L. Ge X. Ju B. Zhang Z. Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization. J. Clin. Virol. 2022 150-151 105162 10.1016/j.jcv.2022.105162 35461042
    [Google Scholar]
  13. Xu S. Yang K. Li R. Zhang L. mRNA vaccine era—mechanisms, drug platform and clinical prospection. Int. J. Mol. Sci. 2020 21 18 6582 10.3390/ijms21186582 32916818
    [Google Scholar]
  14. Idris I. Adesola R.O. Emergence and spread of JN.1 COVID-19 variant. Bull. Natl. Res. Cent. 2024 48 1 27 10.1186/s42269‑024‑01183‑5
    [Google Scholar]
  15. Raisinghani N. Alshahrani M. Gupta G. Verkhivker G. AlphaFold2 modeling and molecular dynamics simulations of the conformational ensembles for the SARS-CoV-2 spike omicron JN.1, KP.2 and KP.3 variants: mutational profiling of binding energetics reveals epistatic drivers of the ACE2 affinity and escape hotspots of antibody resistance. Viruses 2024 16 9 1458 10.3390/v16091458 39339934
    [Google Scholar]
  16. Volz E. Hill V. McCrone J.T. Price A. Jorgensen D. O’Toole Á. Southgate J. Johnson R. Jackson B. Nascimento F.F. Rey S.M. Nicholls S.M. Colquhoun R.M. da Silva Filipe A. Shepherd J. Pascall D.J. Shah R. Jesudason N. Li K. Jarrett R. Pacchiarini N. Bull M. Geidelberg L. Siveroni I. Goodfellow I. Loman N.J. Pybus O.G. Robertson D.L. Thomson E.C. Rambaut A. Connor T.R. Koshy C. Wise E. Cortes N. Lynch J. Kidd S. Mori M. Fairley D.J. Curran T. McKenna J.P. Adams H. Fraser C. Golubchik T. Bonsall D. Moore C. Caddy S.L. Khokhar F.A. Wantoch M. Reynolds N. Warne B. Maksimovic J. Spellman K. McCluggage K. John M. Beer R. Afifi S. Morgan S. Marchbank A. Price A. Kitchen C. Gulliver H. Merrick I. Southgate J. Guest M. Munn R. Workman T. Connor T.R. Fuller W. Bresner C. Snell L.B. Charalampous T. Nebbia G. Batra R. Edgeworth J. Robson S.C. Beckett A. Loveson K.F. Aanensen D.M. Underwood A.P. Yeats C.A. Abudahab K. Taylor B.E.W. Menegazzo M. Clark G. Smith W. Khakh M. Fleming V.M. Lister M.M. Howson-Wells H.C. Berry L. Boswell T. Joseph A. Willingham I. Bird P. Helmer T. Fallon K. Holmes C. Tang J. Raviprakash V. Campbell S. Sheriff N. Loose M.W. Holmes N. Moore C. Carlile M. Wright V. Sang F. Debebe J. Coll F. Signell A.W. Betancor G. Wilson H.D. Feltwell T. Houldcroft C.J. Eldirdiri S. Kenyon A. Davis T. Pybus O. du Plessis L. Zarebski A. Raghwani J. Kraemer M. Francois S. Attwood S. Vasylyeva T. Torok M.E. Hamilton W.L. Goodfellow I.G. Hall G. Jahun A.S. Chaudhry Y. Hosmillo M. Pinckert M.L. Georgana I. Yakovleva A. Meredith L.W. Moses S. Lowe H. Ryan F. Fisher C.L. Awan A.R. Boyes J. Breuer J. Harris K.A. Brown J.R. Shah D. Atkinson L. Lee J.C.D. Alcolea-Medina A. Moore N. Cortes N. Williams R. Chapman M.R. Levett L.J. Heaney J. Smith D.L. Bashton M. Young G.R. Allan J. Loh J. Randell P.A. Cox A. Madona P. Holmes A. Bolt F. Price J. Mookerjee S. Rowan A. Taylor G.P. Ragonnet-Cronin M. Nascimento F.F. Jorgensen D. Siveroni I. Johnson R. Boyd O. Geidelberg L. Volz E.M. Brunker K. Smollett K.L. Loman N.J. Quick J. McMurray C. Stockton J. Nicholls S. Rowe W. Poplawski R. Martinez-Nunez R.T. Mason J. Robinson T.I. O’Toole E. Watts J. Breen C. Cowell A. Ludden C. Sluga G. Machin N.W. Ahmad S.S.Y. George R.P. Halstead F. Sivaprakasam V. Thomson E.C. Shepherd J.G. Asamaphan P. Niebel M.O. Li K.K. Shah R.N. Jesudason N.G. Parr Y.A. Tong L. Broos A. Mair D. Nichols J. Carmichael S.N. Nomikou K. Aranday-Cortes E. Johnson N. Starinskij I. da Silva Filipe A. Robertson D.L. Orton R.J. Hughes J. Vattipally S. Singer J.B. Hale A.D. Macfarlane-Smith L.R. Harper K.L. Taha Y. Payne B.A.I. Burton-Fanning S. Waugh S. Collins J. Eltringham G. Templeton K.E. McHugh M.P. Dewar R. Wastenge E. Dervisevic S. Stanley R. Prakash R. Stuart C. Elumogo N. Sethi D.K. Meader E.J. Coupland L.J. Potter W. Graham C. Barton E. Padgett D. Scott G. Swindells E. Greenaway J. Nelson A. Yew W.C. Resende Silva P.C. Andersson M. Shaw R. Peto T. Justice A. Eyre D. Crooke D. Hoosdally S. Sloan T.J. Duckworth N. Walsh S. Chauhan A.J. Glaysher S. Bicknell K. Wyllie S. Butcher E. Elliott S. Lloyd A. Impey R. Levene N. Monaghan L. Bradley D.T. Allara E. Pearson C. Muir P. Vipond I.B. Hopes R. Pymont H.M. Hutchings S. Curran M.D. Parmar S. Lackenby A. Mbisa T. Platt S. Miah S. Bibby D. Manso C. Hubb J. Chand M. Dabrera G. Ramsay M. Bradshaw D. Thornton A. Myers R. Schaefer U. Groves N. Gallagher E. Lee D. Williams D. Ellaby N. Harrison I. Hartman H. Manesis N. Patel V. Bishop C. Chalker V. Osman H. Bosworth A. Robinson E. Holden M.T.G. Shaaban S. Birchley A. Adams A. Davies A. Gaskin A. Plimmer A. Gatica-Wilcox B. McKerr C. Moore C. Williams C. Heyburn D. De Lacy E. Hilvers E. Downing F. Shankar G. Jones H. Asad H. Coombes J. Watkins J. Evans J.M. Fina L. Gifford L. Gilbert L. Graham L. Perry M. Morgan M. Bull M. Cronin M. Pacchiarini N. Craine N. Jones R. Howe R. Corden S. Rey S. Kumziene-Summerhayes S. Taylor S. Cottrell S. Jones S. Edwards S. O’Grady J. Page A.J. Wain J. Webber M.A. Mather A.E. Baker D.J. Rudder S. Yasir M. Thomson N.M. Aydin A. Tedim A.P. Kay G.L. Trotter A.J. Gilroy R.A.J. Alikhan N-F. de Oliveira Martins L. Le-Viet T. Meadows L. Kolyva A. Diaz M. Bell A. Gutierrez A.V. Charles I.G. Adriaenssens E.M. Kingsley R.A. Casey A. Simpson D.A. Molnar Z. Thompson T. Acheson E. Masoli J.A.H. Knight B.A. Hattersley A. Ellard S. Auckland C. Mahungu T.W. Irish-Tavares D. Haque T. Bourgeois Y. Scarlett G.P. Partridge D.G. Raza M. Evans C. Johnson K. Liggett S. Baker P. Essex S. Lyons R.A. Caller L.G. Castellano S. Williams R.J. Kristiansen M. Roy S. Williams C.A. Dyal P.L. Tutill H.J. Panchbhaya Y.N. Forrest L.M. Niola P. Findlay J. Brooks T.T. Gavriil A. Mestek-Boukhibar L. Weeks S. Pandey S. Berry L. Jones K. Richter A. Beggs A. Smith C.P. Bucca G. Hesketh A.R. Harrison E.M. Peacock S.J. Palmer S. Churcher C.M. Bellis K.L. Girgis S.T. Naydenova P. Blane B. Sridhar S. Ruis C. Forrest S. Cormie C. Gill H.K. Dias J. Higginson E.E. Maes M. Young J. Kermack L.M. Hadjirin N.F. Aggarwal D. Griffith L. Swingler T. Davidson R.K. Rambaut A. Williams T. Balcazar C.E. Gallagher M.D. O’Toole Á. Rooke S. Jackson B. Colquhoun R. Ashworth J. Hill V. McCrone J.T. Scher E. Yu X. Williamson K.A. Stanton T.D. Michell S.L. Bewshea C.M. Temperton B. Michelsen M.L. Warwick-Dugdale J. Manley R. Farbos A. Harrison J.W. Sambles C.M. Studholme D.J. Jeffries A.R. Darby A.C. Hiscox J.A. Paterson S. Iturriza-Gomara M. Jackson K.A. Lucaci A.O. Vamos E.E. Hughes M. Rainbow L. Eccles R. Nelson C. Whitehead M. Turtle L. Haldenby S.T. Gregory R. Gemmell M. Kwiatkowski D. de Silva T.I. Smith N. Angyal A. Lindsey B.B. Groves D.C. Green L.R. Wang D. Freeman T.M. Parker M.D. Keeley A.J. Parsons P.J. Tucker R.M. Brown R. Wyles M. Constantinidou C. Unnikrishnan M. Ott S. Cheng J.K.J. Bridgewater H.E. Frost L.R. Taylor-Joyce G. Stark R. Baxter L. Alam M.T. Brown P.E. McClure P.C. Chappell J.G. Tsoleridis T. Ball J. Grammatopoulos D. Buck D. Todd J.A. Green A. Trebes A. MacIntyre-Cockett G. de Cesare M. Langford C. Alderton A. Amato R. Goncalves S. Jackson D.K. Johnston I. Sillitoe J. Palmer S. Lawniczak M. Berriman M. Danesh J. Livett R. Shirley L. Farr B. Quail M. Thurston S. Park N. Betteridge E. Weldon D. Goodwin S. Nelson R. Beaver C. Letchford L. Jackson D.A. Foulser L. McMinn L. Prestwood L. Kay S. Kane L. Dorman M.J. Martincorena I. Puethe C. Keatley J-P. Tonkin-Hill G. Smith C. Jamrozy D. Beale M.A. Patel M. Ariani C. Spencer-Chapman M. Drury E. Lo S. Rajatileka S. Scott C. James K. Buddenborg S.K. Berger D.J. Patel G. Garcia-Casado M.V. Dibling T. McGuigan S. Rogers H.A. Hunter A.D. Souster E. Neaverson A.S. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell 2021 184 1 64 75.e11 10.1016/j.cell.2020.11.020 33275900
    [Google Scholar]
  17. Huang Q. Wu X. Zheng X. Luo S. Xu S. Weng J. Targeting inflammation and cytokine storm in COVID-19. Pharmacol. Res. 2020 159 105051 10.1016/j.phrs.2020.105051 32603772
    [Google Scholar]
  18. Tay M.Z. Poh C.M. Rénia L. MacAry P.A. Ng L.F.P. The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol. 2020 20 6 363 374 10.1038/s41577‑020‑0311‑8 32346093
    [Google Scholar]
  19. Zheng H.Y. Zhang M. Yang C.X. Zhang N. Wang X.C. Yang X.P. Dong X.Q. Zheng Y.T. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell. Mol. Immunol. 2020 17 5 541 543 10.1038/s41423‑020‑0401‑3 32203186
    [Google Scholar]
  20. Chowdhury M.A. Hossain N. Kashem M.A. Shahid M.A. Alam A. Immune response in COVID-19: A review. J. Infect. Public Health 2020 13 11 1619 1629 10.1016/j.jiph.2020.07.001 32718895
    [Google Scholar]
  21. Gresele P. Momi S. Marcucci R. Ramundo F. De Stefano V. Tripodi A. Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome. Haematologica 2021 106 12 3034 3045 10.3324/haematol.2021.279289 34407607
    [Google Scholar]
  22. Wang L. Berger N.A. Kaelber D.C. Davis P.B. Volkow N.D. Xu R. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. MedRxiv 2022 10.1101/2021.12.30.21268495
    [Google Scholar]
  23. Tirado S.M.C. Yoon K.J. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 2003 16 1 69 86 10.1089/088282403763635465 12725690
    [Google Scholar]
  24. Ricke D.O. Two different antibody-dependent enhancement (ADE) risks for SARS-CoV-2 antibodies. Front. Immunol. 2021 12 640093 10.3389/fimmu.2021.640093 33717193
    [Google Scholar]
  25. Zeng X. Huang X. Xu L. Xiao J. Gu L. Wang Y. Tuo Y. Fang X. Wang W. Li N. Xiao W. Yang Y. Gong P. Song W. Gao J. He X. Huang S. Zeng Y. Wei L. Chen W. Clinical outcomes of dialysis patients with COVID-19 in the initial phase of the COVID-19 outbreak in Wuhan, China. Int. Urol. Nephrol. 2021 53 2 353 357 10.1007/s11255‑020‑02670‑0 33123844
    [Google Scholar]
  26. Livingston E.H. Malani P.N. Creech C.B. The johnson & johnson vaccine for COVID-19. JAMA 2021 325 15 1575 10.1001/jama.2021.2927 33646285
    [Google Scholar]
  27. Aksu S.B. Öztürk G.Z. A rare case of shingles after COVID-19 vaccine: Is it a possible adverse effect? Clin. Exp. Vaccine Res. 2021 10 2 198 201 10.7774/cevr.2021.10.2.198 34222134
    [Google Scholar]
  28. Cagigi A. Loré K. Immune responses induced by mRNA vaccination in mice, monkeys and humans. Vaccines (Basel) 2021 9 1 61 10.3390/vaccines9010061 33477534
    [Google Scholar]
  29. Khurana A. Allawadhi P. Khurana I. Allwadhi S. Weiskirchen R. Banothu A.K. Chhabra D. Joshi K. Bharani K.K. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today 2021 38 101142 10.1016/j.nantod.2021.101142 33815564
    [Google Scholar]
  30. Sethuraman N. Jeremiah S.S. Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA 2020 323 22 2249 2251 10.1001/jama.2020.8259 32374370
    [Google Scholar]
  31. Sheikh A. McMenamin J. Taylor B. Robertson C. SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021 397 10293 2461 2462 10.1016/S0140‑6736(21)01358‑1 34139198
    [Google Scholar]
  32. Chu D.K. Akl E.A. Duda S. Solo K. Yaacoub S. Schünemann H.J. Chu D.K. Akl E.A. El-harakeh A. Bognanni A. Lotfi T. Loeb M. Hajizadeh A. Bak A. Izcovich A. Cuello-Garcia C.A. Chen C. Harris D.J. Borowiack E. Chamseddine F. Schünemann F. Morgano G.P. Muti Schünemann G.E.U. Chen G. Zhao H. Neumann I. Chan J. Khabsa J. Hneiny L. Harrison L. Smith M. Rizk N. Giorgi Rossi P. AbiHanna P. El-khoury R. Stalteri R. Baldeh T. Piggott T. Zhang Y. Saad Z. Khamis A. Reinap M. Duda S. Solo K. Yaacoub S. Schünemann H.J. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and meta-analysis. Lancet 2020 395 10242 1973 1987 10.1016/S0140‑6736(20)31142‑9 32497510
    [Google Scholar]
  33. Polinski J.M. Weckstein A.R. Batech M. Kabelac C. Kamath T. Harvey R. Jain S. Rassen J.A. Khan N. Schneeweiss S. Effectiveness of the single-dose Ad26. COV2. S COVID vaccine. MedRxiv 2021 3385 10.1101/2021.09.10.21263385
    [Google Scholar]
  34. Butt A.A. Talisa V.B. Yan P. Shaikh O.S. Omer S.B. Mayr F.B. Real-world effectiveness of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines in preventing confirmed infection in patients on chronic hemodialysis. Clin. Infect. Dis. 2022 75 1 e617 e622 10.1093/cid/ciac118 35139175
    [Google Scholar]
  35. Tegally H. Wilkinson E. Giovanetti M. Iranzadeh A. Fonseca V. Giandhari J. Doolabh D. Pillay S. San E.J. Msomi N. Mlisana K. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medrxiv 2020 10.1101/2020.12.21.20248640
    [Google Scholar]
  36. Wang P. Casner R.G. Nair M.S. Wang M. Yu J. Cerutti G. Liu L. Kwong P.D. Huang Y. Shapiro L. Ho D.D. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe 2021 29 5 747 751.e4 10.1016/j.chom.2021.04.007 33887205
    [Google Scholar]
  37. Wu F. Zhao S. Yu B. Chen Y.M. Wang W. Song Z.G. Hu Y. Tao Z.W. Tian J.H. Pei Y.Y. Yuan M.L. Zhang Y.L. Dai F.H. Liu Y. Wang Q.M. Zheng J.J. Xu L. Holmes E.C. Zhang Y.Z. A new coronavirus associated with human respiratory disease in China. Nature 2020 579 7798 265 269 10.1038/s41586‑020‑2008‑3 32015508
    [Google Scholar]
  38. Zhou Z. Zhao N. Shu Y. Han S. Chen B. Shu X. Effect of gastrointestinal symptoms in patients with COVID-19. Gastroenterology 2020 158 8 2294 2297 10.1053/j.gastro.2020.03.020 32199880
    [Google Scholar]
  39. Martínez-Baz I. Trobajo-Sanmartín C. Miqueleiz A. Guevara M. Fernández-Huerta M. Burgui C. Casado I. Portillo M.E. Navascués A. Ezpeleta C. Castilla J. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveill. 2021 26 39 2100894 10.2807/1560‑7917.ES.2021.26.39.2100894 34596016
    [Google Scholar]
  40. Boloko L. Lifson A. Little F. De Wet T. Papavarnavas N. Marais G. Hsiao N.Y. Rosslee M.J. Doolabh D. Iranzadeh A. Williamson C. Severity and inpatient mortality of COVID-19 pneumonia from Beta variant infection: A clinical cohort study in Cape Town, South Africa. medRxiv 2021 5916 10.1101/2021.11.04.21265916
    [Google Scholar]
  41. Bruxvoort KJ Sy LS Qian L Ackerson BK Luo Y Lee GS Tian Y Florea A Aragones M Tubert JE Takhar HS Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: Test negative case-control study. BMJ 2021 375
    [Google Scholar]
  42. Mina M.J. Parker R. Larremore D.B. Rethinking Covid-19 test sensitivity—a strategy for containment. N. Engl. J. Med. 2020 383 22 e120 10.1056/NEJMp2025631 32997903
    [Google Scholar]
  43. Flaxman S. Mishra S. Gandy A. Unwin H.J.T. Mellan T.A. Coupland H. Whittaker C. Zhu H. Berah T. Eaton J.W. Monod M. Perez-Guzman P.N. Schmit N. Cilloni L. Ainslie K.E.C. Baguelin M. Boonyasiri A. Boyd O. Cattarino L. Cooper L.V. Cucunubá Z. Cuomo-Dannenburg G. Dighe A. Djaafara B. Dorigatti I. van Elsland S.L. FitzJohn R.G. Gaythorpe K.A.M. Geidelberg L. Grassly N.C. Green W.D. Hallett T. Hamlet A. Hinsley W. Jeffrey B. Knock E. Laydon D.J. Nedjati-Gilani G. Nouvellet P. Parag K.V. Siveroni I. Thompson H.A. Verity R. Volz E. Walters C.E. Wang H. Wang Y. Watson O.J. Winskill P. Xi X. Walker P.G.T. Ghani A.C. Donnelly C.A. Riley S. Vollmer M.A.C. Ferguson N.M. Okell L.C. Bhatt S. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020 584 7820 257 261 10.1038/s41586‑020‑2405‑7 32512579
    [Google Scholar]
  44. Sinclair J.E. Mayfield H.J. Short K.R. Brown S.J. Puranik R. Mengersen K. Litt J.C. Lau C.L. Quantifying the risks versus benefits of the Pfizer COVID-19 vaccine in Australia: A Bayesian network analysis. medRxiv 2022 637 10.1101/2022.02.07.22270637
    [Google Scholar]
  45. Jung S.Y. Kim B.G. Kwon D. Park J.H. Youn S.K. Jeon S. Um H.Y. Kwon K.E. Kim H.J. Jung H.J. Choi E. Park B.J. An outbreak of joint and cutaneous infections caused by non-tuberculous mycobacteria after corticosteroid injection. Int. J. Infect. Dis. 2015 36 62 69 10.1016/j.ijid.2015.05.018 26026822
    [Google Scholar]
  46. Markel H. Lipman H.B. Navarro J.A. Sloan A. Michalsen J.R. Stern A.M. Cetron M.S. Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic. JAMA 2007 298 6 644 654 10.1001/jama.298.6.644 17684187
    [Google Scholar]
  47. Hale T. Angrist N. Goldszmidt R. Kira B. Petherick A. Phillips T. Webster S. Cameron-Blake E. Hallas L. Majumdar S. Tatlow H. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). Nat. Hum. Behav. 2021 5 4 529 538 10.1038/s41562‑021‑01079‑8 33686204
    [Google Scholar]
  48. Lam T.T.Y. Jia N. Zhang Y.W. Shum M.H.H. Jiang J.F. Zhu H.C. Tong Y.G. Shi Y.X. Ni X.B. Liao Y.S. Li W.J. Jiang B.G. Wei W. Yuan T.T. Zheng K. Cui X.M. Li J. Pei G.Q. Qiang X. Cheung W.Y.M. Li L.F. Sun F.F. Qin S. Huang J.C. Leung G.M. Holmes E.C. Hu Y.L. Guan Y. Cao W.C. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 2020 583 7815 282 285 10.1038/s41586‑020‑2169‑0 32218527
    [Google Scholar]
  49. Wang C. Liu L. Hao X. Guo H. Wang Q. Huang J. He N. Yu H. Lin X. Pan A. Wei S. Evolving epidemiology and impact of non-pharmaceutical interventions on the outbreak of coronavirus disease 2019 in Wuhan, China. MedRxiv 2020 593 10.1101/2020.03.03.20030593
    [Google Scholar]
  50. Linares-Fernández S. Lacroix C. Exposito J.Y. Verrier B. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends Mol. Med. 2020 26 3 311 323 10.1016/j.molmed.2019.10.002 31699497
    [Google Scholar]
  51. Schoenmaker L. Witzigmann D. Kulkarni J.A. Verbeke R. Kersten G. Jiskoot W. Crommelin D.J.A. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int. J. Pharm. 2021 601 120586 10.1016/j.ijpharm.2021.120586 33839230
    [Google Scholar]
  52. Jüni P. Rothenbühler M. Bobos P. Thorpe K.E. da Costa B.R. Fisman D.N. Slutsky A.S. Gesink D. Impact of climate and public health interventions on the COVID-19 pandemic: A prospective cohort study. CMAJ 2020 192 21 E566 E573 10.1503/cmaj.200920 32385067
    [Google Scholar]
  53. Reynolds L. Dewey C. Asfour G. Little M. Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: A systematic review. Front. Public Health 2023 11 1229716 10.3389/fpubh.2023.1229716 37942238
    [Google Scholar]
  54. Al-Rousan N. Al-Najjar H. Evaluation of the effects of MERCK, MODERNA, PFIZER/BioNTech, and JANSSEN COVID-19 vaccines on vaccinated people: A metadata analysis. Inform. Med. Unlocked 2024 49 101564 10.1016/j.imu.2024.101564
    [Google Scholar]
  55. Shabu A. Nishtala P.S. Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): A literature review. Expert Rev. Vaccines 2023 22 1 393 409 10.1080/14760584.2023.2209177 37133747
    [Google Scholar]
  56. Arias-Murillo YR Salinas-Nova MA Caicedo T Galindo-Borda M Meneses-Gil X Montero C Giron F Pedraza N Aroca G Ospina-Martinez ML Mercado-Reyes M Low performance of Sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patients. Transplantation Proceedings Elsevier 2023 55 3 500 507
    [Google Scholar]
  57. Issa Y.W. Salih S.M. Evaluating the Effectiveness of Pfizer, AstraZeneca, and Sinopharm Vaccines Against COVID-19 in Iraq: A Cross-Sectional Study of Vaccine Efficacy and Symptom Severity. Journal of Madenat Alelem University College. 2024 16 1 11 21
    [Google Scholar]
  58. Majumder J. Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J. 2021 23 1 14 10.1208/s12248‑020‑00532‑2 33400058
    [Google Scholar]
  59. Tchesnokov E.P. Gordon C.J. Woolner E. Kocinkova D. Perry J.K. Feng J.Y. Porter D.P. Götte M. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. J. Biol. Chem. 2020 295 47 16156 16165 10.1074/jbc.AC120.015720 32967965
    [Google Scholar]
  60. Frediansyah A. Tiwari R. Sharun K. Dhama K. Harapan H. Antivirals for COVID-19: A critical review. Clin. Epidemiol. Glob. Health 2021 9 90 98 10.1016/j.cegh.2020.07.006 33521390
    [Google Scholar]
  61. Gottlieb R.L. Vaca C.E. Paredes R. Mera J. Webb B.J. Perez G. Oguchi G. Ryan P. Nielsen B.U. Brown M. Hidalgo A. Sachdeva Y. Mittal S. Osiyemi O. Skarbinski J. Juneja K. Hyland R.H. Osinusi A. Chen S. Camus G. Abdelghany M. Davies S. Behenna-Renton N. Duff F. Marty F.M. Katz M.J. Ginde A.A. Brown S.M. Schiffer J.T. Hill J.A. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med. 2022 386 4 305 315 10.1056/NEJMoa2116846 34937145
    [Google Scholar]
  62. Spinner C.D. Gottlieb R.L. Criner G.J. Arribas López J.R. Cattelan A.M. Soriano Viladomiu A. Ogbuagu O. Malhotra P. Mullane K.M. Castagna A. Chai L.Y.A. Roestenberg M. Tsang O.T.Y. Bernasconi E. Le Turnier P. Chang S.C. SenGupta D. Hyland R.H. Osinusi A.O. Cao H. Blair C. Wang H. Gaggar A. Brainard D.M. McPhail M.J. Bhagani S. Ahn M.Y. Sanyal A.J. Huhn G. Marty F.M. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA 2020 324 11 1048 1057 10.1001/jama.2020.16349 32821939
    [Google Scholar]
  63. Sanders J.M. Monogue M.L. Jodlowski T.Z. Cutrell J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 2020 323 18 1824 1836 10.1001/jama.2020.6019 32282022
    [Google Scholar]
  64. Hashemian S.M.R. Sheida A. Taghizadieh M. Memar M.Y. Hamblin M.R. Bannazadeh Baghi H. Sadri Nahand J. Asemi Z. Mirzaei H. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? Biomed. Pharmacother. 2023 162 114367 10.1016/j.biopha.2023.114367 37018987
    [Google Scholar]
  65. Mahapatro A. Singh D.K. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J. Nanobiotechnolo. 2011 9 1 55 10.1186/1477‑3155‑9‑55 22123084
    [Google Scholar]
  66. Szunerits S. Barras A. Khanal M. Pagneux Q. Boukherroub R. Nanostructures for the inhibition of viral infections. Molecules 2015 20 8 14051 14081 10.3390/molecules200814051 26247927
    [Google Scholar]
  67. Majumder J. Taratula O. Minko T. Nanocarrier-based systems for targeted and site specific therapeutic delivery. Adv. Drug Deliv. Rev. 2019 144 57 77 10.1016/j.addr.2019.07.010 31400350
    [Google Scholar]
  68. Cojocaru F.D. Botezat D. Gardikiotis I. Uritu C.M. Dodi G. Trandafir L. Rezus C. Rezus E. Tamba B.I. Mihai C.T. Nanomaterials designed for antiviral drug delivery transport across biological barriers. Pharmaceutics 2020 12 2 171 10.3390/pharmaceutics12020171 32085535
    [Google Scholar]
  69. Coleman C.M. Liu Y.V. Mu H. Taylor J.K. Massare M. Flyer D.C. Glenn G.M. Smith G.E. Frieman M.B. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014 32 26 3169 3174 10.1016/j.vaccine.2014.04.016 24736006
    [Google Scholar]
  70. Huang X. Li M. Xu Y. Zhang J. Meng X. An X. Sun L. Guo L. Shan X. Ge J. Chen J. Luo Y. Wu H. Zhang Y. Jiang Q. Ning X. Novel gold nanorod-based HR1 peptide inhibitor for Middle East respiratory syndrome coronavirus. ACS Appl. Mater. Interfaces 2019 11 22 19799 19807 10.1021/acsami.9b04240 31099550
    [Google Scholar]
  71. Lammers T. SMART drug delivery systems: Back to the future vs. clinical reality. Int. J. Pharm. 2013 454 1 527 529 10.1016/j.ijpharm.2013.02.046 23485339
    [Google Scholar]
  72. van der Meel R. Sulheim E. Shi Y. Kiessling F. Mulder W.J.M. Lammers T. Smart cancer nanomedicine. Nat. Nanotechnol. 2019 14 11 1007 1017 10.1038/s41565‑019‑0567‑y 31695150
    [Google Scholar]
  73. Cheng Y. Wong R. Soo Y.O.Y. Wong W.S. Lee C.K. Ng M.H.L. Chan P. Wong K.C. Leung C.B. Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 2005 24 1 44 46 10.1007/s10096‑004‑1271‑9 15616839
    [Google Scholar]
  74. Chen L. Xiong J. Bao L. Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 2020 20 4 398 400 10.1016/S1473‑3099(20)30141‑9 32113510
    [Google Scholar]
  75. Shen C. Wang Z. Zhao F. Yang Y. Li J. Yuan J. Wang F. Li D. Yang M. Xing L. Wei J. Xiao H. Yang Y. Qu J. Qing L. Chen L. Xu Z. Peng L. Li Y. Zheng H. Chen F. Huang K. Jiang Y. Liu D. Zhang Z. Liu Y. Liu L. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020 323 16 1582 1589 10.1001/jama.2020.4783 32219428
    [Google Scholar]
  76. Joyner M.J. Wright R.S. Fairweather D. Senefeld J.W. Bruno K.A. Klassen S.A. Carter R.E. Klompas A.M. Wiggins C.C. Shepherd J.R.A. Rea R.F. Whelan E.R. Clayburn A.J. Spiegel M.R. Johnson P.W. Lesser E.R. Baker S.E. Larson K.F. Ripoll J.G. Andersen K.J. Hodge D.O. Kunze K.L. Buras M.R. Vogt M.N.P. Herasevich V. Dennis J.J. Regimbal R.J. Bauer P.R. Blair J.E. Van Buskirk C.M. Winters J.L. Stubbs J.R. Paneth N.S. Verdun N.C. Marks P. Casadevall A. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J. Clin. Invest. 2020 130 9 4791 4797 10.1172/JCI140200 32525844
    [Google Scholar]
  77. Marston H.D. Paules C.I. Fauci A.S. Monoclonal antibodies for emerging infectious diseases—borrowing from history. N. Engl. J. Med. 2018 378 16 1469 1472 10.1056/NEJMp1802256 29513615
    [Google Scholar]
  78. ter Meulen J. Bakker A.B.H. van den Brink E.N. Weverling G.J. Martina B.E.E. Haagmans B.L. Kuiken T. de Kruif J. Preiser W. Spaan W. Gelderblom H.R. Goudsmit J. Osterhaus A.D.M.E. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004 363 9427 2139 2141 10.1016/S0140‑6736(04)16506‑9 15220038
    [Google Scholar]
  79. Xu XW Wu XX Jiang XG Xu KJ Ying LJ Ma CL Li SB Wang HY Zhang S Gao HN Sheng JF Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: Retrospective case series BMJ 2020 Feb 19 368
    [Google Scholar]
  80. Puoci F. “Monoclonal-Type” plastic antibodies for COVID-19 treatment: What Is the Idea? J. Funct. Biomater. 2020 11 2 43 10.3390/jfb11020043 32560382
    [Google Scholar]
  81. Chen P. Nirula A. Heller B. Gottlieb R.L. Boscia J. Morris J. Huhn G. Cardona J. Mocherla B. Stosor V. Shawa I. Adams A.C. Van Naarden J. Custer K.L. Shen L. Durante M. Oakley G. Schade A.E. Sabo J. Patel D.R. Klekotka P. Skovronsky D.M. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N. Engl. J. Med. 2021 384 3 229 237 10.1056/NEJMoa2029849 33113295
    [Google Scholar]
  82. Hansen J. Baum A. Pascal K.E. Russo V. Giordano S. Wloga E. Fulton B.O. Yan Y. Koon K. Patel K. Chung K.M. Hermann A. Ullman E. Cruz J. Rafique A. Huang T. Fairhurst J. Libertiny C. Malbec M. Lee W. Welsh R. Farr G. Pennington S. Deshpande D. Cheng J. Watty A. Bouffard P. Babb R. Levenkova N. Chen C. Zhang B. Romero Hernandez A. Saotome K. Zhou Y. Franklin M. Sivapalasingam S. Lye D.C. Weston S. Logue J. Haupt R. Frieman M. Chen G. Olson W. Murphy A.J. Stahl N. Yancopoulos G.D. Kyratsous C.A. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 2020 369 6506 1010 1014 10.1126/science.abd0827 32540901
    [Google Scholar]
  83. Baum A. Fulton B.O. Wloga E. Copin R. Pascal K.E. Russo V. Giordano S. Lanza K. Negron N. Ni M. Wei Y. Atwal G.S. Murphy A.J. Stahl N. Yancopoulos G.D. Kyratsous C.A. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 2020 369 6506 1014 1018 10.1126/science.abd0831 32540904
    [Google Scholar]
  84. Weinreich D.M. Sivapalasingam S. Norton T. Ali S. Gao H. Bhore R. Musser B.J. Soo Y. Rofail D. Im J. Perry C. Pan C. Hosain R. Mahmood A. Davis J.D. Turner K.C. Hooper A.T. Hamilton J.D. Baum A. Kyratsous C.A. Kim Y. Cook A. Kampman W. Kohli A. Sachdeva Y. Graber X. Kowal B. DiCioccio T. Stahl N. Lipsich L. Braunstein N. Herman G. Yancopoulos G.D. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N. Engl. J. Med. 2021 384 3 238 251 10.1056/NEJMoa2035002 33332778
    [Google Scholar]
  85. Kip K.E. McCreary E.K. Collins K. Minnier T.E. Snyder G.M. Garrard W. McKibben J.C. Yealy D.M. Seymour C.W. Huang D.T. Bariola J.R. Schmidhofer M. Wadas R.J. Angus D.C. Kip P.L. Marroquin O.C. Evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19: A cohort study. Ann. Intern. Med. 2023 176 4 496 504 10.7326/M22‑1286 37011399
    [Google Scholar]
  86. Leggat P.A. Frean J. Blumberg L. COVID-19: Current status and future prospects. Trop. Med. Infect. Dis. 2023 8 2 94 10.3390/tropicalmed8020094 36828510
    [Google Scholar]
  87. Moolla M.S. Maponga T.G. Moolla H. Kollenberg E. Anie S. Moolla A. Moodley D. Lalla U. Allwood B.W. Schrueder N. Preiser W. Koegelenberg C.F.N. Parker A. A tale of two waves: Characteristics and outcomes of COVID-19 admissions during the Omicron-driven fourth wave in Cape Town, South Africa, and implications for the future. IJID Reg. 2023 6 42 47 10.1016/j.ijregi.2022.11.008 36448029
    [Google Scholar]
  88. Rehman A. Xing H. Adnan khan M. Hussain M. Hussain A. Gulzar N. Emerging technologies for COVID (ET-CoV) detection and diagnosis: Recent advancements, applications, challenges, and future perspectives. Biomed. Signal Process. Control 2023 83 104642 10.1016/j.bspc.2023.104642 36818992
    [Google Scholar]
  89. Al-Rousan N. Al-Najjar H. Evaluation of the effects of MERCK, MODERNA, PFIZER/BioNTech, and JANSSEN COVID-19 vaccines on vaccinated people: A metadata analysis. Informat. Medi. Unloc. 2024 49 101564
    [Google Scholar]
  90. Arias-Murillo Y.R. Salinas-Nova M.A. Caicedo T. Galindo-Borda M. Meneses-Gil X. Montero C. Giron F. Pedraza N. Aroca G. Ospina-Martinez M.L. Mercado-Reyes M. Low performance of Sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patients. Transplant. Proc. 2023 55 3 500 507 10.1016/j.transproceed.2023.02.034 36997378
    [Google Scholar]
/content/journals/covid/10.2174/0126667975278624241224101531
Loading
COVID 19: Variants, Diagnosis and Vaccines- An Update
Bentham Science Publishers ; https://doi.org/10.2174/0126667975278624241224101531
/content/journals/covid/10.2174/0126667975278624241224101531
/content/journals/covid/10.2174/0126667975278624241224101531
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: COVID-19 ; SARS-Cov 2 ; diagnostic ; vaccines ; antiviral ; variants
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test